The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers

Cell Cycle

Volumn 13, Issue 9, 2014, Pages 1413-1423

  Iyer, R Sumanth ^a   Nicol, Samantha M ^a   Quinlan, Philip R ^a   Thompson, Alastair M ^a,b   Meek, David W ^a   Fuller Pace, Frances V ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Gene expression; P53; P68; PLK1

Indexed keywords

ETOPOSIDE; POLO LIKE KINASE 1; PROTEIN P53; PROTEIN P68; RNA HELICASE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DDX5 PROTEIN, HUMAN; DEAD BOX PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; WILD TYPE; BREAST TUMOR; COHORT ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COHORT STUDIES; DEAD-BOX RNA HELICASES; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899745691     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28415     Document Type: Article

References (56)

1. Dardenne E, Pierredon S, Driouch K, Gratadou L, Lacroix-Triki M, Espinoza MP, Zonta E, Germann S, Mortada H, Villemin JP, et al. Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol 2012; 19:1139-46; PMID:23022728; http://dx.doi.org/10.1038/nsmb. 2390
2. Guil S, Gattoni R, Carrascal M, Abián J, Stévenin J, Bach-Elias M. Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation. Mol Cell Biol 2003; 23:2927-41; PMID:12665590; http://dx.doi.org/10.1128/MCB.23.8.2927-2941.2003
3. Liu ZR. p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5′ splice site duplex. Mol Cell Biol 2002; 22:5443-50; PMID:12101238; http://dx.doi.org/10.1128/MCB.22.15.5443-5450.2002
4. Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshida I, Yoshimura K, Mihara M, Naitou M, Endoh H, Nakamura T, et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 2007; 9:604-11; PMID:17435748; http://dx.doi.org/10. 1038/ncb1577
5. Jalal C, Uhlmann-Schiffler H, Stahl H. Redundant role of DEAD box proteins p68 (Ddx5) and p72/ p82 (Ddx17) in ribosome biogenesis and cell proliferation. Nucleic Acids Res 2007; 35:3590-601; PMID:17485482; http://dx.doi.org/10.1093/nar/gkm058
6. Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 2008; 68:7938-46; PMID:18829551; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-0932
7. Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM, Shousha S, Huson L, Bray SE, et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene 2009; 28:4053-64; PMID:19718048; http://dx.doi.org/10.1038/onc.2009.261
8. Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV. The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 2005; 24:543-53; PMID:15660129; http://dx.doi.org/10.1038/sj.emboj.7600550
9. Métivier R, Penot G, Hübner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115:751-63; PMID:14675539; http://dx.doi.org/10.1016/S0092-8674(03)00934-6
10. Yang L, Lin C, Zhao S, Wang H, Liu ZR. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 2007; 282:16811-9; PMID:17412694; http://dx.doi.org/10.1074/jbc.M610488200
11. Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, Steele RJ, Fuller-Pace FV. Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene 2001; 20:7734-43; PMID:11753651; http://dx.doi.org/10.1038/sj.onc.1204976
12. Shin S, Rossow KL, Grande JP, Janknecht R. Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 2007; 67:7572-8; PMID:17699760; http://dx.doi.org/10.1158/0008-5472.CAN-06-4652
13. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395
14. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147
15. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037
16. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223:116-26; PMID:21125670; http://dx.doi.org/10.1002/path.2784
17. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15:2-8; PMID:23263379; http://dx.doi.org/10.1038/ncb2641
18. Nicol SM, Bray SE, Black HD, Lorimore SA, Wright EG, Lane DP, Meek DW, Coates PJ, Fuller-Pace FV. The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell-cycle arrest after DNA damage. Oncogene 2013; 32:3461-9; PMID:22986526; http://dx.doi.org/10.1038/ onc.2012.426
19. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009; 10:265-75; PMID:19305416; http://dx.doi.org/10.1038/nrm2653
20. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60; PMID:20671765; http://dx.doi.org/10.1038/nrd3184
21. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30; PMID:16557283; http://dx.doi.org/10.1038/nrc1841
22. Dietzmann K, Kirches E, von Bossanyi, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001; 53:1-11; PMID:11678424; http://dx.doi.org/10.1023/A:1011808200978
23. Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90:414-8; PMID:14735186; http://dx.doi.org/10.1038/sj.bjc.6601540
24. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:2794-7; PMID:10383133
25. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of pololike kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29:354-8; PMID:12135466; http://dx.doi.org/10.1034/j.1600-0560.2002.290605.x
26. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94:148-52; PMID:12708489; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01411.x
27. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of pololike kinase expression in esophageal carcinoma. Int J Oncol 1999; 15:687-92; PMID:10493949
28. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, Dietel M, Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90:815-21; PMID:14970859; http://dx.doi.org/10.1038/sj.bjc.6601610
29. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Müller BM, Niesporek S, Dietel M, Denkert C. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch 2005; 446:442-50; PMID:15785925; http://dx.doi.org/10.1007/s00428-005-1212-8
30. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60:240-5; PMID:15176053; http://dx.doi.org/10.1002/pros.20050
31. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14:543-9; PMID:9053852; http://dx.doi.org/10.1038/sj.onc.1200862
32. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23:5901-11; PMID:15221005; http://dx.doi.org/10.1038/sj.onc.1207782
33. Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196:753-9; PMID:11186170
34. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Pololike kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279:25549-61; PMID:15024021; http://dx.doi.org/10.1074/jbc.M314182200
35. Incassati A, Patel D, McCance DJ. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6. Oncogene 2006; 25:2444-51; PMID:16369493; http://dx.doi.org/10.1038/sj.onc.1209276
36. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 2004; 279:21183-92; PMID:15016801; http://dx.doi.org/10. 1074/jbc.M311912200
37. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2:672-6; PMID:10980711; http://dx.doi.org/10.1038/35023629
38. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr., Kinzler KW, Vogelstein B, Papadopoulos N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106:3964-9; PMID:19225112; http://dx.doi.org/10.1073/pnas.0813333106
39. van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005; 24:2844-59; PMID:15838519; http://dx.doi.org/10.1038/ sj.onc.1208617
40. van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. J Biol Chem 2001; 276:41656-60; PMID:11514540; http://dx.doi.org/10.1074/jbc.M101831200
41. Zhu H, Chang BD, Uchiumi T, Roninson IB. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1). Cell Cycle 2002; 1:59-66; PMID:12429910; http://dx.doi.org/10.4161/cc.1.1.101
42. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9:4200-12; PMID:20962589; http://dx.doi.org/10.4161/cc.9.20.13532
43. King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res 2012; 14:R40; PMID:22405092; http://dx.doi.org/10.1186/bcr3136
44. Hirling H, Scheffner M, Restle T, Stahl H. RNA helicase activity associated with the human p68 protein. Nature 1989; 339:562-4; PMID:2471939; http://dx.doi.org/10.1038/339562a0
45. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501; PMID:9822382; http://dx.doi.org/10. 1126/science.282.5393.1497
46. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009; 9:307; PMID:19723334; http://dx.doi.org/10.1186/1471-2407-9-307
47. Caretti G, Schiltz RL, Dilworth FJ, Di Padova M, Zhao P, Ogryzko V, Fuller-Pace FV, Hoffman EP, Tapscott SJ, Sartorelli V. The RNA helicases p68/ p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell 2006; 11:547-60; PMID:17011493; http://dx.doi.org/10. 1016/j.devcel.2006.08.003
48. Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS, Stillman B. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov 2012; 2:812-25; PMID:22750847; http://dx.doi.org/10.1158/2159-8290.CD-12-0116
49. Rossow KL, Janknecht R. Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300. Oncogene 2003; 22:151-6; PMID:12527917; http://dx.doi.org/10.1038/sj.onc.1206067
50. Buszczak M, Spradling AC. The Drosophila P68 RNA helicase regulates transcriptional deactivation by promoting RNA release from chromatin. Genes Dev 2006; 20:977-89; PMID:16598038; http://dx.doi.org/10.1101/gad.1396306
51. Lin C, Yang L, Yang JJ, Huang Y, Liu ZR. ATPase/ helicase activities of p68 RNA helicase are required for pre-mRNA splicing but not for assembly of the spliceosome. Mol Cell Biol 2005; 25:7484-93; PMID:16107697; http://dx.doi.org/ 10.1128/MCB.25.17.7484-7493.2005
52. Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, Mann DA, Walsh MJ, Sninsky JJ, Friedman SLA. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem 2010; 285:5428-37; PMID:20022962; http://dx.doi.org/10.1074/jbc.M109.035295
53. Moore HC, Jordan LB, Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon JC, Fuller- Pace FV. The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer. Oncogene 2010; 29:6475-84; PMID:20818423; http://dx.doi.org/10.1038/onc.2010.381
54. Baker L, Quinlan PR, Patten N, Ashfield A, Birse- Stewart-Bell LJ, McCowan C, Bourdon JC, Purdie CA, Jordan LB, Dewar JA, et al. p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 2010; 102:719-26; PMID:20104224; http://dx.doi.org/10.1038/sj.bjc.6605540
55. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48:876-8; PMID:7490328; http://dx.doi.org/10.1136/jcp.48.9.876
56. Quinlan PR, Reed C, Thompson A. INSPIRE: an integrated agent based system for hypothesis generation within cancer datasets. WI-IAT 2008; 3:587-90, 2008 IEEE/WIC/ACM International Conference on Web Intellegence and Intellegent Agent Technology.